Novartis reported Q3 sales growth and core margin expansion, with the stock up 1.5% after earnings—within the roughly flat range. Full-year 2026 bottom-line guidance was raised, while management said meaningful acceleration in Pluvicto’s hormone-sensitive prostate cancer launch is more likely next year.
Novartis reported robust Q3 2025 results with a 7% increase in sales and core operating income, driven by strong performance from key growth drivers and critical pipeline advancements.